Key result
Fluoropyrimidine-based chemotherapy for colorectal cancer can induce cardiotoxic effects, primarily coronary vasospasm, which may be managed with vasodilators for secondary prevention.
Why the study?
Fluoropyrimidines are mainstays in treating gastrointestinal cancers, but their therapy can cause cardiotoxic effects that are complex and difficult to predict.
Answers are grounded in this paper and cite their sources.
Fluoropyrimidines used in colorectal cancer treatment can cause complex cardiotoxicity, which may be managed with vasodilating drugs for secondary prevention.
Fluoropyrimidines (5-fluorouracil, capecitabine) are the main chemotherapeutic agents in the treatment of gastrointestinal oncologic pathology. However, therapy with these drugs may be associated with the development of cardiotoxic effects. The article discusses risk factors, the main proven mechanisms of cardiotoxic effects development; possible measures of primary and secondary prevention, peculiarities of fluoropyrimidines cardiotoxicity treatment are outlined. Clinical cases are presented that demonstrate the complexity of the pathophysiological mechanisms of development of fluoropyrimidine (capecitabine) cardiotoxicity and the difficulties of its prediction. In this case, drugs with a vasodilating effect can be effectively used as part of secondary prevention.
No takes yet. Share an insight, caveat, or question.
Klimkin et al. (2023) conducted a review in Colorectal cancer. Fluoropyrimidines (5-fluorouracil, capecitabine) was evaluated. Fluoropyrimidine-based chemotherapy for colorectal cancer can induce cardiotoxic effects, primarily coronary vasospasm, which may be managed with vasodilators for secondary prevention.
Synapse has enriched 10 related papers. Consider them for comparative context: